Verification and optimization of the VTE risk stratification system for multiple myeloma
An improved blood clot risk score for multiple myeloma patients outperforms current methods and could guide preventive treatment.
An optimized VTE risk stratification system for newly diagnosed multiple myeloma integrating thromboprophylaxis status achieved AUC 0.742 in derivation and 0.730 in external validation, significantly outperforming the current IMWG score (AUC 0.605). Three clinically accessible risk factors (sex, bed rest, platelet count) may improve thromboprophylaxis guidance in Chinese MM patients.
What the study was
- Study design
- Retrospective cohort with internal and external validation
- Population
- Newly diagnosed multiple myeloma (NDMM) patients; n=433 (derivation=332, validation=101)
- Sample size
- 433
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Journal of Thrombosis and Thrombolysis
Why it surfaced
Clinically relevant VTE risk tool for MM; internal and external validation; modest AUC improvement but practically significant for thromboprophylaxis decisions.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.